Stockscreener 앱 받기
20.91
0.14%
0.03
전일 마감가:
$20.88
열려 있는:
$20.76
하루 거래량:
1.47M
Relative Volume:
1.61
시가총액:
$1.20B
수익:
-
순이익/손실:
$-100.44M
주가수익비율:
-9.4189
EPS:
-2.22
순현금흐름:
$-105.32M
1주 성능:
-5.30%
1개월 성능:
+11.58%
6개월 성능:
-2.38%
1년 성능:
-48.10%
1일 변동 폭
$20.29
$21.49
1주일 범위
$20.29
$22.08
52주 변동 폭
$13.22
$45.37
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
명칭
Structure Therapeutics Inc Adr
전화
(628) 229-9277
주소
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
GPCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
20.91 | 1.20B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-02 | 개시 | Citigroup | Buy |
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-12-04 | 개시 | H.C. Wainwright | Buy |
| 2024-09-23 | 개시 | Morgan Stanley | Overweight |
| 2024-05-21 | 개시 | JP Morgan | Overweight |
| 2024-04-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2023-07-27 | 개시 | Piper Sandler | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2023-02-28 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | Guggenheim | Buy |
| 2023-02-28 | 개시 | Jefferies | Buy |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Sold by Exome Asset Management LLC - MarketBeat
Brokers Issue Forecasts for GPCR Q3 Earnings - MarketBeat
Cubist Systematic Strategies LLC Has $949,000 Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Rating Increased to Strong-Buy at Lifesci Capital - MarketBeat
This Under-the-Radar Healthcare Stock Could Soar in 2026 - The Globe and Mail
Zimmer Partners LP Raises Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Trexquant Investment LP Grows Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Optimistic Buy Rating for Structure Therapeutics Driven by Aleniglipron’s Potential in Obesity and T2D Markets - TipRanks
First-Ever Structural Analysis: Armata's Therapeutic Phage Pa223 Shows Promise for Antibiotic-Resistant Infections - Stock Titan
Structure Therapeutics (NASDAQ:GPCR) Trading Up 5.3%Time to Buy? - MarketBeat
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Purchased by Vestal Point Capital LP - MarketBeat
Point72 Europe London LLP Purchases 59,277 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Novan (NOVN) - The Globe and Mail
Jump Financial LLC Buys New Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
DAFNA Capital Management LLC Has $1.02 Million Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Tema Etfs LLC Lowers Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Obesity Drug Developer Structure Therapeutics to Present at Major Healthcare Conferences in September - Stock Titan
Quantbot Technologies LP Invests $249,000 in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
American Century Companies Inc. Has $8.83 Million Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Layoff Tracker: Novartis Continues Cutting Spree With 58 Sacked in New Jersey - BioSpace
Analysts Are Bullish on Top Healthcare Stocks: OnKure Therapeutics (OKUR), Inventiva (IVA) - The Globe and Mail
American Century Companies Inc. Has $8.83 Million Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Invesco Ltd. Boosts Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Microsoft Corporation $MSFT Stock Holdings Cut by Alpine Woods Capital Investors LLC - Defense World
Analyzing Leap Technology (OTCMKTS:LPTC) and Molina Healthcare (NYSE:MOH) - Defense World
Promotora de Informaciones (OTCMKTS:PRISY) Trading 20.3% Higher – Still a Buy? - Defense World
ArcelorMittal South Africa (OTCMKTS:AMSIY) Trading Down 23.2% – What’s Next? - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Rating of "Buy" from Analysts - MarketBeat
Enterprise Group (TSE:E) Given a C$2.42 Price Target at Fundamental Research - Defense World
Culp (CULP) to Release Quarterly Earnings on Wednesday - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Buy” by Brokerages - Defense World
Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints - Bergen Record
Analysts’ Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE) - The Globe and Mail
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Protara Therapeutics (TARA), Annexon Biosciences (ANNX) and Agilent (A) - The Globe and Mail
Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform - MarketScreener
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors - The Motley Fool
Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity - PR Newswire
Structure Therapeutics’ SWOT analysis: oral GLP-1 stock faces pivotal phase - Investing.com
SEED Therapeutics Named Finalist for 2025 Prix Galien USA 'Best Start-Up” Award - The Manila Times
Can Structure Therapeutics’ (GPCR) Aggressive Funding Moves Accelerate Its Obesity Drug Ambitions? - Yahoo Finance
ABSSSI Pipeline 2025: Detailed Clinical Trials - openPR.com
Up 23% to 132%, There's Still Time to Buy These 3 Stocks - The Globe and Mail
Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules - Stock Titan
FY2025 EPS Estimates for GPCR Lowered by Cantor Fitzgerald - Defense World
William Blair Has Bearish Forecast for GPCR Q3 Earnings - Defense World
FY2025 EPS Estimates for GPCR Decreased by HC Wainwright - Defense World
Leerink Partnrs Has Negative Forecast for GPCR Q3 Earnings - Defense World
Leerink Partnrs Issues Negative Outlook for GPCR Earnings - Defense World
PepGen Inc.’s Promising Clinical Developments and Strategic Advancements Earn a Buy Rating - TipRanks
Why Is Everyone Talking About UnitedHealth Group Stock? - The Globe and Mail
Structure Therapeutics Inc Adr (GPCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
0.10%
자본화:
|
볼륨(24시간):